TY - JOUR
T1 - Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure
T2 - A multicenter retrospective study
AU - Chanan-Khan, Asher A.
AU - Kaufman, Jonathan L.
AU - Mehta, Jayesh
AU - Richardson, Paul G.
AU - Miller, Kena C.
AU - Lonial, Sagar
AU - Munshi, Nikhil C.
AU - Schlossman, Robert
AU - Tariman, Joseph
AU - Singhal, Seema
PY - 2007/3/15
Y1 - 2007/3/15
N2 - Patients with multiple myeloma (MM) frequently present with concomitant renal dysfunction, and those requiring dialysis have particularly poor outcomes. Bortezomib is a reversible proteasome inhibitor with significant activity in MM. This retrospective case analysis evaluated the feasibility and activity of bortezomib-based therapy in MM patients (n = 24) requiring dialysis support for advanced renal failure. All but 1 patient were undergoing dialysis at the time of therapy. Patients received bortezomib alone or bortezomib-based combination therapy. Among 20 patients with available response data, overall response rate (complete response [CR] + partial response) was 75%, with 30% CR + near CR. One patient was spared dialysis, and 3 other patients became independent of dialysis following bortezomib-based treatment. These encouraging results suggest that bortezomib or bortezomib-based regimens can be used in MM patients requiring dialysis, with manageable toxicities. Further studies will more formally evaluate the impact of bortezomib-based regimens in this patient population.
AB - Patients with multiple myeloma (MM) frequently present with concomitant renal dysfunction, and those requiring dialysis have particularly poor outcomes. Bortezomib is a reversible proteasome inhibitor with significant activity in MM. This retrospective case analysis evaluated the feasibility and activity of bortezomib-based therapy in MM patients (n = 24) requiring dialysis support for advanced renal failure. All but 1 patient were undergoing dialysis at the time of therapy. Patients received bortezomib alone or bortezomib-based combination therapy. Among 20 patients with available response data, overall response rate (complete response [CR] + partial response) was 75%, with 30% CR + near CR. One patient was spared dialysis, and 3 other patients became independent of dialysis following bortezomib-based treatment. These encouraging results suggest that bortezomib or bortezomib-based regimens can be used in MM patients requiring dialysis, with manageable toxicities. Further studies will more formally evaluate the impact of bortezomib-based regimens in this patient population.
UR - http://www.scopus.com/inward/record.url?scp=33947201310&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33947201310&partnerID=8YFLogxK
U2 - 10.1182/blood-2006-09-046409
DO - 10.1182/blood-2006-09-046409
M3 - Article
C2 - 17138816
AN - SCOPUS:33947201310
SN - 0006-4971
VL - 109
SP - 2604
EP - 2606
JO - Blood
JF - Blood
IS - 6
ER -